Quantcast Ardelyx Inc Stock Quote | Stock Price for ARDX | Financial News | myMotherLode.com

Financial News

Motherlode Stocks
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Ardelyx Inc (NQ: ARDX)
3.890 USD  -0.030 (-0.77%)
Official Closing Price  /  Updated: 4:43 PM EDT, Oct 19, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 167,500
Open 3.930
Bid (Size) 3.500 (1)
Ask (Size) 4.350 (30)
Prev. Close 3.920
Today's Range 3.840 - 4.090
52wk Range 3.550 - 8.100
Shares Outstanding 60,103,568
Dividend Yield N/A
Performance
YTD
-44.43%
-44.43%
1 Month
-7.38%
-7.38%
3 Month
-9.53%
-9.53%
6 Month
-16.34%
-16.34%
1 Year
-29.27%
-29.27%
Top News
More News
Analysis: Positioning to Benefit within Ardelyx, AXT, TG Therapeutics, MarineMax, Oclaro, and BioCryst Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ardelyx, Inc.... Read More
from GlobeNewswire News Releases
Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting
Ardelyx, Inc. (Nasdaq: ARDX), today announced that new data from its long-term safety trial of tenapanor for irritable bowel syndrome with constipation (IBS-C), the T3MPO-3 trial, were presented this... Read More
from PR Newswire
More News
Read More
Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders
from PR Newswire
Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration
from PR Newswire
Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption
from PR Newswire
Consolidated Research: 2018 Summary Expectations for PDF Solutions, MYOS RENS Technology, Aldeyra Therapeutics, The Ensign Group, Everi, and Ardelyx — Fundamental Analysis, Key Performance Indications
from GlobeNewswire News Releases
Ardelyx Reports Second Quarter 2018 Financial Results and Recent Highlights
from PR Newswire
Ardelyx Announces Date of Second Quarter 2018 Financial Results and Conference Call
from PR Newswire
Free Technical Research Reports on Biotech Stocks -- Versartis, VIVUS, Xenetic Biosciences, and Ardelyx
from PR Newswire
Consolidated Research: 2018 Summary Expectations for CorVel, Consol Energy, Ardelyx, Aevi Genomic Medicine, Proofpoint, and Brink's — Fundamental Analysis, Key Performance Indications
from GlobeNewswire News Releases
Ardelyx to Present at the Jefferies 2018 Global Healthcare Conference
from PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Follow myMotherLode.com at these social networks Make Us Your Homepage Today Follow us on Facebook Follow us on Twitter Follow us on Youtube Follow us on LinkedIn Follow our RSS Feed
Yellow Pages

Popular Searches

Local Radio Stations
© Copyright 2000-2017 Clarke Broadcasting Corporation. All rights reserved.